Appointment of VP for North America
2011年12月6日 - 7:42PM
RNSニュース (英語)
TIDMNGG
NextGen Group PLC
06 December 2011
NextGen Sciences Appoints Steve Zolnay as Vice President of
Business Development for North America
Ann Arbor, Michigan, US, and London, UK, 6 December 2011 -
NextGen Group plc (AIM:NGG) is pleased to announce that its
US-subsidiary NextGen Sciences Inc, a leader in biomarker
discovery, measurement and qualification, has appointed Steve
Zolnay as Vice President of Business Development for North
America.
Zolnay, a graduate from Dartmouth College with a degree in
Biology, started his professional career at the Dana Farber Cancer
Institute in Boston Massachusetts where he investigated the over
expression of the Her2/Neu oncogene and its roles in Breast Cancer.
In 1990, he moved over to the business side of science. He has
successfully held various sales and business development positions
interacting with Pharmaceutical, Biotech and Academic Institutions.
Key positions that Zolnay has held include: Director of Sales North
America for The Automation Partnership Cell Culture Automation
Division, Vice President Business Development for Nanostream and
Worldwide Director of Sales for Blue Sky Biotech. He is also
President of Protein Attachment Technologies, an early stage
Biotech company focusing on membrane associated cancer targets.
Klaus Rosenau, Chairman and CEO of NextGen Group, commented:
"Steve brings a rich scientific background, a deep understanding of
the application of technologies and services to pharma, biotech and
diagnostic product development. Steve also brings many strong
personal connections to leaders within the industry and will be
instrumental in generating value for our customers and shareholders
in the growing biomarker market".
NextGen has continuously expanded its product offerings by
introducing a series of technically validated human multiplex
plasma assays for oncology and CSF assays for CNS diseases.
NextGen's assays are based upon its multiple reaction monitoring
(MRM) mass spectrometry platform that generate highly data with
high specificity and precision which clients can utilize in their
drug and diagnostic development programmes. The MRM platform can be
used to assay proteins and modified proteins for which there are no
antibodies and can thus circumvent the limitations of current
antibody based technologies. NextGen expects to develop further
oncology and CNS disease-focused assay panels, both as proprietary
products and with other companies, through partnerships and
collaborations.
- ENDS -
For more information please contact :
NextGen Group
Klaus Rosenau, Chairman and CEO
klaus.rosenau@nextgensciences.com
+49 160 551 6756
Seymour Pierce
Jonathan Wright, Nicola Marrin
+44 (0) 20 7107 8000
Notes to Editors
NextGen Sciences Inc (Ann Arbor, MI, USA) is the subsidiary of
NextGen Group PLC, London, UK (AIM: NGG). It provides
pharmaceutical, biotechnology and diagnostic companies with rapid
and quantitative protein biomarker discovery, measurement and
qualification services using mass spectrometry technology. With a
rise in the industry focus on personalised medicine and
cost-effectiveness, biomarkers are playing an increasing important
role in drug discovery, development and patient access, as well as
healthcare delivery. The global market for biomarkers is expected
to grow to $12.8bn by 2012 (BCC Research), with those for
neurological disorders ($3.5bn by 2015, Espicom Healthcare) and
oncology ($9.5bn by 2014, www.marketsandmarkets.com) playing an
important role. NextGen Sciences' products include Discovery
Assays, CNS Assays, Oncology Assays and Custom Assays . For more
information visit www.nextgensciences.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRADKADQKBDDDBK
Nextgen (LSE:NGG)
過去 株価チャート
から 5 2024 まで 6 2024
Nextgen (LSE:NGG)
過去 株価チャート
から 6 2023 まで 6 2024